MARGARET SPITZ to Treatment Outcome
This is a "connection" page, showing publications MARGARET SPITZ has written about Treatment Outcome.
Connection Strength
0.137
-
Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics. 2008 Nov; 18(11):955-65.
Score: 0.024
-
Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. Clin Cancer Res. 2006 Dec 01; 12(23):7194-201.
Score: 0.021
-
Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol. 2005 Jan 10; 23(2):267-75.
Score: 0.019
-
Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiol Biomarkers Prev. 2002 Nov; 11(11):1413-8.
Score: 0.016
-
Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy. Clin Pharmacol Ther. 2014 Sep; 96(3):360-369.
Score: 0.009
-
Eliminating second-hand smoke from Mexican-American households: outcomes from Project Clean Air-Safe Air (CASA). Addict Behav. 2013 Jan; 38(1):1485-92.
Score: 0.008
-
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res. 2012 Jul 01; 18(13):3705-13.
Score: 0.008
-
Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. J Cancer Res Clin Oncol. 2012 Mar; 138(3):377-85.
Score: 0.008
-
Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst. 2011 May 18; 103(10):817-25.
Score: 0.007
-
Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila). 2011 Feb; 4(2):185-93.
Score: 0.007
-
High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):2894-8.
Score: 0.005
-
Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate. 2004 Sep 01; 60(4):343-51.
Score: 0.005